Arcticzymes Technologies ASA logo

AZTo - Arcticzymes Technologies ASA Share Price

NOK78 2.4  3.2%

Last Trade - 5:00pm

Small Cap
Market Cap £340.0m
Enterprise Value £329.3m
Revenue £7.88m
Position in Universe 569th / 1850
Unlock AZTo Revenue
Relative Strength (%)
1m -3.55%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
53.3 71.9 66.7 66.8 45.2 93.4 +11.9%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Arcticzymes Technologies ASA revenues increased fromNOK45.2M to NOK93.4M. Net income applicable to commonstockholders excluding extraordinary items totaled NOK75.4Mvs. loss of NOK570K. Revenues reflect an increase in demandfor the Company's products and services due to favorablemarket conditions. Net Income reflects Other Revenuesincrease of 10% to NOK4.4M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AZTo Revenue Unlock AZTo Revenue

Net Income

AZTo Net Income Unlock AZTo Revenue

Normalised EPS

AZTo Normalised EPS Unlock AZTo Revenue

PE Ratio Range

AZTo PE Ratio Range Unlock AZTo Revenue

Dividend Yield Range

AZTo Dividend Yield Range Unlock AZTo Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AZTo EPS Forecasts Unlock AZTo Revenue
Profile Summary

Arcticzymes Technologies ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 12, 1995
Public Since November 4, 2005
No. of Shareholders: n/a
No. of Employees: 38
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Shares in Issue 48,334,673
Free Float (0.0%)
Eligible for
AZTo Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AZTo
Upcoming Events for AZTo
Frequently Asked Questions for Arcticzymes Technologies ASA
What is the Arcticzymes Technologies ASA share price?

As of 5:00pm, shares in Arcticzymes Technologies ASA are trading at NOK78, giving the company a market capitalisation of £340.0m. This share price information is delayed by 15 minutes.

How has the Arcticzymes Technologies ASA share price performed this year?

Shares in Arcticzymes Technologies ASA are currently trading at NOK78 and the price has moved by 0.941k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arcticzymes Technologies ASA price has moved by 0.888k% over the past year.

What are the analyst and broker recommendations for Arcticzymes Technologies ASA?

There are no analysts currently covering Arcticzymes Technologies ASA.

When will Arcticzymes Technologies ASA next release its financial results?

Arcticzymes Technologies ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Arcticzymes Technologies ASA dividend yield?

Arcticzymes Technologies ASA does not currently pay a dividend.

Does Arcticzymes Technologies ASA pay a dividend?

Arcticzymes Technologies ASA does not currently pay a dividend.

When does Arcticzymes Technologies ASA next pay dividends?

Arcticzymes Technologies ASA does not currently pay a dividend.

How do I buy Arcticzymes Technologies ASA shares?

To buy shares in Arcticzymes Technologies ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arcticzymes Technologies ASA?

Shares in Arcticzymes Technologies ASA are currently trading at NOK78, giving the company a market capitalisation of £340.0m.

Where are Arcticzymes Technologies ASA shares listed? Where are Arcticzymes Technologies ASA shares listed?

Here are the trading details for Arcticzymes Technologies ASA:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: AZTo
What kind of share is Arcticzymes Technologies ASA?

Based on an overall assessment of its quality, value and momentum, Arcticzymes Technologies ASA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arcticzymes Technologies ASA share price forecast 2021?

Shares in Arcticzymes Technologies ASA are currently priced at NOK78. At that level they are trading at 77.51% premium to the analyst consensus target price of 0.00.

How can I tell whether the Arcticzymes Technologies ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcticzymes Technologies ASA. Over the past six months, the relative strength of its shares against the market has been -0.32%. At the current price of NOK78, shares in Arcticzymes Technologies ASA are trading at 0.126k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arcticzymes Technologies ASA PE Ratio?

The Arcticzymes Technologies ASA PE ratio based on its reported earnings over the past 12 months is 63.56. The shares are currently trading at NOK78.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Arcticzymes Technologies ASA?

Arcticzymes Technologies ASA's management team is headed by:

Rolf Engstad - CSO
Gerd Nilsen - DRC
Borge Sorvoll - CFO
Masha Le Gris Stromme - DRC
Jethro Holter - CEO
Martin Hunt - DRC
Marie Roskrow - CHM
Finn Ketler - OTH
Volker Wedershoven - DRC
Marit Sjo Lorentzen - DRC
Who are the major shareholders of Arcticzymes Technologies ASA?

Here are the top five shareholders of Arcticzymes Technologies ASA based on the size of their shareholding:

SEB Investment Management AB Investment Advisor
Percentage owned: 8.81% (4.26m shares)
Pro AS Corporation
Percentage owned: 4.75% (2.30m shares)
Vinterstua AS Corporation
Percentage owned: 4.23% (2.04m shares)
Ormestad (Tellef) Individual Investor
Percentage owned: 2.69% (1.30m shares)
Sandberg (Jon Rømer) Individual Investor
Percentage owned: 2.52% (1.22m shares)
Similar to AZTo
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.